Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23446454 | 0.96 | GLO1 (0.39) | GLO1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL24235726 | 0.93 | GLO1 (0.38) | GLO1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL23446816 | 0.90 | KMT2A (0.42) | GLO1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL24235778 | 0.86 | GLP1R (0.43) | KMT2ANOD1CAPN1 | |
| SCHEMBL7257742 | 0.85 | L3MBTL1 (0.38) | KMT2APOLBL3MBTL1LTA4HCTSS | |
| SCHEMBL24235578 | 0.84 | L3MBTL1 (0.32) | GLO1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL9688654 | 0.83 | KMT2A (0.43) | GLO1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL10421162 | 0.83 | KMT2A (0.43) | GLO1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL9689060 | 0.83 | KMT2A (0.43) | GLO1PTGS1GSTK1KMT2APOLB | |
| SCHEMBL9689026 | 0.83 | KMT2A (0.43) | GLO1PTGS1GSTK1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793881-B2 | Polyethylene glycol conjugate medicament, preparation method therefor and use thereof | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-10-24 | — | — | US | disclosed |
| WO-2022022360-A1 | POLYETHYLENE GLYCOL CONJUGATE DRUG, AND PREPARATION METHOD THERFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793881-B2 | Polyethylene glycol conjugate medicament, preparation method therefor and use thereof | SLC10A1, SLC10A2, NOTUM | GLO1 1337/4885PTGS1 678/4885GSTK1 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.